News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Daiichi Sankyo Co Ltd. Upbeat on Drug to Prevent Strokes and Clots
February 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Feb 21 (Reuters) - Japan's Daiichi Sankyo Co Ltd said on Thursday it was highly satisfied with mid-stage results for a key drug to prevent strokes and clots, and would move on to late-stage trials despite fierce competition in the field.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Asia
Europe
Daiichi Sankyo
MORE ON THIS TOPIC
Infectious disease
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
December 19, 2025
·
2 min read
·
Tristan Manalac
ADCs
Patient Deaths Put Merck, Daiichi Sankyo’s Antibody-Drug Conjugate on Hold
December 19, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data
December 19, 2025
·
2 min read
·
Tristan Manalac
Deals
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
December 18, 2025
·
1 min read
·
BioSpace Insights
